SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3u7s'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_1
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.56A 1c6yA-3u7sA:
19.3		 1c6yA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_1
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.58A 1c6yA-3u7sA:
19.3		 1c6yA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_2
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.42A 1c6yB-3u7sA:
19.1		 1c6yB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Y_B_MK1B524_2
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.63A 1c6yB-3u7sA:
19.1		 1c6yB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_1
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.45A 1c6zA-3u7sA:
19.3		 1c6zA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_1
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.51A 1c6zA-3u7sA:
19.3		 1c6zA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_2
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.56A 1c6zB-3u7sA:
19.2		 1c6zB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1C6Z_B_ROCB505_2
(PROTEIN (PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.62A 1c6zB-3u7sA:
19.2		 1c6zB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4S_A_TPVA201_1
(PROTEIN (HIV-1
PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.55A 1d4sA-3u7sA:
19.9		 1d4sA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4S_A_TPVA201_1
(PROTEIN (HIV-1
PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.30A 1d4sA-3u7sA:
19.9		 1d4sA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4Y_A_TPVA501_1
(PROTEIN (HIV-1
PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.44A 1d4yA-3u7sA:
20.0		 1d4yA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1D4Y_A_TPVA501_1
(PROTEIN (HIV-1
PROTEASE))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.35A 1d4yA-3u7sA:
20.0		 1d4yA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1FB7_A_ROCA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.34A 1fb7A-3u7sA:
19.7		 1fb7A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1FB7_A_ROCA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.39A 1fb7A-3u7sA:
19.7		 1fb7A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HPV_B_478B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 1hpvA-3u7sA:
20.2		 1hpvA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HPV_B_478B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.42A 1hpvB-3u7sA:
20.2		 1hpvB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSG_B_MK1B902_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.47A 1hsgA-3u7sA:
19.8		 1hsgA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSG_B_MK1B902_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.54A 1hsgB-3u7sA:
19.7		 1hsgB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_A_MK1A401_1
(HIV-II PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.50A 1hshA-3u7sA:
19.0		 1hshA-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_A_MK1A401_1
(HIV-II PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.41A 1hshA-3u7sA:
19.0		 1hshA-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_A_MK1A401_2
(HIV-II PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.60A 1hshB-3u7sA:
19.1		 1hshB-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_C_MK1C402_1
(HIV-II PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.52A 1hshC-3u7sA:
19.2		 1hshC-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HSH_C_MK1C402_1
(HIV-II PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.53A 1hshC-3u7sA:
19.2		 1hshC-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.47A 1hxbA-3u7sA:
19.9		 1hxbA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  48
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.44A 1hxbA-3u7sA:
19.9		 1hxbA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 1hxbB-3u7sA:
20.0		 1hxbB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 1hxbB-3u7sA:
20.0		 1hxbB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXB_A_ROCA100_4
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 4 GLY A  27
ASP A  29
GLY A  48
THR A  80
 017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
None
 0.34A 1hxbB-3u7sA:
20.0		 1hxbB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXW_B_RITB301_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ASP A  25
GLY A  27
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 1hxwA-3u7sA:
20.0		 1hxwA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXW_B_RITB301_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.53A 1hxwB-3u7sA:
19.5		 1hxwB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1HXW_B_RITB301_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.70A 1hxwB-3u7sA:
19.5		 1hxwB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1K6C_B_MK1B902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 1k6cA-3u7sA:
19.9		 1k6cA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1K6C_B_MK1B902_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.47A 1k6cB-3u7sA:
19.8		 1k6cB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1K6C_B_MK1B902_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.57A 1k6cB-3u7sA:
19.8		 1k6cB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1MUI_B_AB1B100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 1muiA-3u7sA:
19.5		 1muiA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1MUI_B_AB1B100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 1muiB-3u7sA:
20.1		 1muiB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_B_RITB301_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.84A 1n49B-3u7sA:
19.3		 1n49B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1N49_D_RITD401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.85A 1n49C-3u7sA:
19.2		 1n49C-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_1
(ASPARTYLPROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.57A 1ohrA-3u7sA:
19.9		 1ohrA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_1
(ASPARTYLPROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.46A 1ohrA-3u7sA:
19.9		 1ohrA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_2
(ASPARTYLPROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.60A 1ohrB-3u7sA:
19.0		 1ohrB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OHR_A_1UNA201_2
(ASPARTYLPROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 LEU A  23
ASP A  25
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 1ohrB-3u7sA:
19.0		 1ohrB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.42A 1rl8A-3u7sA:
19.7		 1rl8A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 1rl8A-3u7sA:
19.7		 1rl8A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ALA A  22
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
 1.36A 1rl8A-3u7sA:
19.7		 1rl8A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.37A 1rl8B-3u7sA:
19.7		 1rl8B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 1rl8B-3u7sA:
19.7		 1rl8B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ALA A  22
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
 1.37A 1rl8B-3u7sA:
19.7		 1rl8B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1RL8_A_RITA9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  24
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ALA A  22
 None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
 1.42A 1rl8B-3u7sA:
19.7		 1rl8B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDT_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.72A 1sdtA-3u7sA:
20.1		 1sdtA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDT_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.87A 1sdtA-3u7sA:
20.1		 1sdtA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDT_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.68A 1sdtB-3u7sA:
19.6		 1sdtB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.68A 1sduA-3u7sA:
20.0		 1sduA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.63A 1sduA-3u7sA:
20.0		 1sduA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  48
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.54A 1sduA-3u7sA:
20.0		 1sduA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.51A 1sduA-3u7sA:
20.0		 1sduA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDU_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.64A 1sduB-3u7sA:
19.7		 1sduB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.69A 1sdvA-3u7sA:
20.1		 1sdvA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.90A 1sdvA-3u7sA:
20.1		 1sdvA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SDV_B_MK1B902_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.70A 1sdvB-3u7sA:
19.5		 1sdvB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SGU_B_MK1B2632_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.41A 1sguB-3u7sA:
20.3		 1sguB-3u7sA:
84.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SGU_B_MK1B2632_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ALA A  22
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
 1.35A 1sguB-3u7sA:
20.3		 1sguB-3u7sA:
84.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SGU_B_MK1B2632_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 1sguB-3u7sA:
20.3		 1sguB-3u7sA:
84.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SH9_B_RITB301_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ASP A  25
GLY A  27
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.60A 1sh9B-3u7sA:
20.0		 1sh9B-3u7sA:
84.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 1t3rA-3u7sA:
20.0		 1t3rA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.65A 1t3rB-3u7sA:
19.7		 1t3rB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.78A 1t3rB-3u7sA:
19.7		 1t3rB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T3R_A_017A1200_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 1t3rB-3u7sA:
19.7		 1t3rB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7I_A_017A200_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.36A 1t7iA-3u7sA:
19.7		 1t7iA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7I_A_017A200_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 ASP A  25
ALA A  28
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 1t7iB-3u7sA:
19.5		 1t7iB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
THR A  80
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
None
 1.42A 1t7jA-3u7sA:
19.8		 1t7jA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.45A 1t7jA-3u7sA:
19.8		 1t7jA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.40A 1t7jA-3u7sA:
19.8		 1t7jA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T7J_A_478A200_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 ASP A  25
ALA A  28
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.45A 1t7jB-3u7sA:
19.6		 1t7jB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AOH_C_FRDC305_1
(POL POLYPROTEIN
PEPTIDE INHIBITOR)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 5 LEU A  23
ASP A  25
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.40A 2aohA-3u7sA:
20.2		 2aohA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AOJ_C_FRDC305_1
(POL POLYPROTEIN
PEPTIDE INHIBITOR)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 5 LEU A  23
ASP A  25
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.34A 2aojA-3u7sA:
20.0		 2aojA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AQU_B_DR7B300_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.45A 2aquA-3u7sA:
19.9		 2aquA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AQU_B_DR7B300_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.48A 2aquB-3u7sA:
19.9		 2aquB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AQU_B_DR7B300_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 2aquB-3u7sA:
19.9		 2aquB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVO_B_MK1B902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.74A 2avoA-3u7sA:
19.8		 2avoA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVO_B_MK1B902_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ARG A   8
ASP A  25
GLY A  27
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.78A 2avoB-3u7sA:
19.7		 2avoB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVO_B_MK1B902_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.56A 2avoB-3u7sA:
19.7		 2avoB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.50A 2avsA-3u7sA:
20.1		 2avsA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  48
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
 1.29A 2avsA-3u7sA:
20.1		 2avsA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  48
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
 0.41A 2avsA-3u7sA:
20.1		 2avsA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVS_B_MK1B902_3
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.58A 2avsB-3u7sA:
19.6		 2avsB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_A_MK1A901_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  48
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.55A 2avvA-3u7sA:
19.7		 2avvA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_A_MK1A901_3
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.43A 2avvB-3u7sA:
19.9		 2avvB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_A_MK1A901_3
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.48A 2avvB-3u7sA:
19.9		 2avvB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.46A 2avvD-3u7sA:
19.9		 2avvD-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  48
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
 1.22A 2avvD-3u7sA:
19.9		 2avvD-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_3
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.43A 2avvE-3u7sA:
19.8		 2avvE-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2AVV_E_MK1E902_3
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.50A 2avvE-3u7sA:
19.8		 2avvE-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B60_B_RITB100_1
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.47A 2b60A-3u7sA:
20.3		 2b60A-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B60_B_RITB100_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 2b60B-3u7sA:
20.1		 2b60B-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B60_B_RITB100_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  32
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-2.9A)
 0.47A 2b60B-3u7sA:
20.1		 2b60B-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B60_B_RITB100_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 2b60B-3u7sA:
20.1		 2b60B-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B60_B_RITB100_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 GLY A  27
ALA A  28
ASP A  29
ILE A  32
GLY A  49
PRO A  81
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 2b60B-3u7sA:
20.1		 2b60B-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B7Z_B_MK1B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		11 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.54A 2b7zA-3u7sA:
20.3		 2b7zA-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2B7Z_B_MK1B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		11 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.55A 2b7zB-3u7sA:
20.2		 2b7zB-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2BPX_B_MK1B902_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.50A 2bpxB-3u7sA:
19.3		 2bpxB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.25A 2f80A-3u7sA:
19.9		 2f80A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 2f80A-3u7sA:
19.9		 2f80A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.25A 2f80B-3u7sA:
19.8		 2f80B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F80_B_017B301_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.36A 2f80B-3u7sA:
19.8		 2f80B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 2f81A-3u7sA:
20.1		 2f81A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.47A 2f81A-3u7sA:
20.1		 2f81A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.23A 2f81B-3u7sA:
19.7		 2f81B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F81_A_017A302_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.35A 2f81B-3u7sA:
19.7		 2f81B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F8G_B_017B401_1
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 0.20A 2f8gA-3u7sA:
20.2		 2f8gA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F8G_B_017B401_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.65A 2f8gB-3u7sA:
19.6		 2f8gB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F8G_B_017B401_2
(POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 2f8gB-3u7sA:
19.6		 2f8gB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_1
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.38A 2fxdA-3u7sA:
19.0		 2fxdA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_1
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
VAL A  84
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.46A 2fxdA-3u7sA:
19.0		 2fxdA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 ARG A   8
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.40A 2fxdB-3u7sA:
19.8		 2fxdB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.43A 2fxdB-3u7sA:
19.8		 2fxdB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.65A 2fxdB-3u7sA:
19.8		 2fxdB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXD_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.25A 2fxdB-3u7sA:
19.8		 2fxdB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXE_A_DR7A102_1
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  48
GLY A  49
ILE A  50
PHE A  53
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.58A 2fxeA-3u7sA:
19.9		 2fxeA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXE_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.39A 2fxeB-3u7sA:
19.7		 2fxeB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2FXE_A_DR7A102_2
(POL PROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 2fxeB-3u7sA:
19.7		 2fxeB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.48A 2hs1A-3u7sA:
18.4		 2hs1A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 2hs1A-3u7sA:
18.4		 2hs1A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  32
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
None
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 2hs1B-3u7sA:
19.7		 2hs1B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS1_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 2hs1B-3u7sA:
19.7		 2hs1B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.57A 2hs2A-3u7sA:
18.5		 2hs2A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.34A 2hs2A-3u7sA:
18.5		 2hs2A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.41A 2hs2A-3u7sA:
18.5		 2hs2A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-4.0A)
 0.48A 2hs2B-3u7sA:
19.9		 2hs2B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.25A 2hs2B-3u7sA:
19.9		 2hs2B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HS2_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.38A 2hs2B-3u7sA:
19.9		 2hs2B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.53A 2idwA-3u7sA:
19.7		 2idwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 2idwA-3u7sA:
19.7		 2idwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IDW_B_017B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.31A 2idwB-3u7sA:
19.7		 2idwB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEN_B_017B402_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.61A 2ienA-3u7sA:
20.0		 2ienA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEN_B_017B402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.34A 2ienB-3u7sA:
19.8		 2ienB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEN_B_017B402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.53A 2ienB-3u7sA:
19.8		 2ienB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEN_B_017B402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.32A 2ienB-3u7sA:
19.8		 2ienB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.31A 2ieoA-3u7sA:
20.0		 2ieoA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.61A 2ieoA-3u7sA:
20.0		 2ieoA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 2ieoA-3u7sA:
20.0		 2ieoA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 2ieoB-3u7sA:
19.9		 2ieoB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IEO_A_017A402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.34A 2ieoB-3u7sA:
19.9		 2ieoB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.41A 2nmyA-3u7sA:
19.2		 2nmyA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		11 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.69A 2nmyA-3u7sA:
19.2		 2nmyA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.35A 2nmyB-3u7sA:
19.0		 2nmyB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.40A 2nmyB-3u7sA:
19.0		 2nmyB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.55A 2nmyB-3u7sA:
19.0		 2nmyB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMY_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.55A 2nmyB-3u7sA:
19.0		 2nmyB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMZ_B_ROCB401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.48A 2nmzB-3u7sA:
19.5		 2nmzB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NMZ_B_ROCB401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.64A 2nmzB-3u7sA:
19.5		 2nmzB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.26A 2nnkA-3u7sA:
19.6		 2nnkA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.43A 2nnkA-3u7sA:
19.6		 2nnkA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
 0.51A 2nnkA-3u7sA:
19.6		 2nnkA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
None
 0.42A 2nnkA-3u7sA:
19.6		 2nnkA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ASP A  29
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.46A 2nnkB-3u7sA:
19.8		 2nnkB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.22A 2nnkB-3u7sA:
19.8		 2nnkB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNK_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		11 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.49A 2nnkB-3u7sA:
19.8		 2nnkB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 0.93A 2nnpA-3u7sA:
19.7		 2nnpA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.41A 2nnpA-3u7sA:
19.7		 2nnpA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.65A 2nnpA-3u7sA:
19.7		 2nnpA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2NNP_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.47A 2nnpB-3u7sA:
19.7		 2nnpB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  48
GLY A  49
ILE A  50
PHE A  53
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.59A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  48
GLY A  49
PHE A  53
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
None
 0.57A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.61A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  48
GLY A  49
ILE A  50
PHE A  53
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 1.47A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 LEU A  82
ILE A  47
GLY A  48
GLY A  49
PHE A  53
 017  A 202 (-4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
None
 0.68A 2o4kA-3u7sA:
19.9		 2o4kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.38A 2o4kB-3u7sA:
19.7		 2o4kB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4K_A_DR7A301_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 2o4kB-3u7sA:
19.7		 2o4kB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4L_A_TPVA403_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.49A 2o4lA-3u7sA:
19.9		 2o4lA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4N_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		12 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
LEU A  82
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
017  A 202 (-4.0A)
 0.79A 2o4nA-3u7sA:
19.9		 2o4nA-3u7sA:
82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4N_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.34A 2o4nA-3u7sA:
19.9		 2o4nA-3u7sA:
82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4N_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  82
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
 017  A 202 (-4.0A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.21A 2o4nA-3u7sA:
19.9		 2o4nA-3u7sA:
82.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 2o4pA-3u7sA:
19.8		 2o4pA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.28A 2o4pA-3u7sA:
19.8		 2o4pA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 11 LEU A  82
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 (-4.0A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.95A 2o4pA-3u7sA:
19.8		 2o4pA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4P_A_TPVA300_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.45A 2o4pB-3u7sA:
19.5		 2o4pB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 2o4sA-3u7sA:
20.0		 2o4sA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.57A 2o4sB-3u7sA:
19.6		 2o4sB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.68A 2o4sB-3u7sA:
19.6		 2o4sB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.66A 2o4sB-3u7sA:
19.6		 2o4sB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2O4S_A_AB1A400_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.68A 2o4sB-3u7sA:
19.6		 2o4sB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.34A 2pymA-3u7sA:
20.1		 2pymA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.35A 2pymA-3u7sA:
20.1		 2pymA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.36A 2pymA-3u7sA:
20.1		 2pymA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.48A 2pymB-3u7sA:
20.0		 2pymB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 3.5A)
 0.52A 2pymB-3u7sA:
20.0		 2pymB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.37A 2pymB-3u7sA:
20.0		 2pymB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYM_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.43A 2pymB-3u7sA:
20.0		 2pymB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.32A 2pynA-3u7sA:
20.6		 2pynA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.31A 2pynA-3u7sA:
20.6		 2pynA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.50A 2pynB-3u7sA:
20.5		 2pynB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.47A 2pynB-3u7sA:
20.5		 2pynB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PYN_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		3 / 3 ASP A  29
THR A  80
PRO A  81
 017  A 201 (-3.2A)
None
017  A 202 (-4.0A)
 0.23A 2pynB-3u7sA:
20.5		 2pynB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 2q5kA-3u7sA:
19.5		 2q5kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.36A 2q5kA-3u7sA:
19.5		 2q5kA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.68A 2q5kB-3u7sA:
19.8		 2q5kB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q5K_A_AB1A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.77A 2q5kB-3u7sA:
19.8		 2q5kB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.51A 2q63B-3u7sA:
20.2		 2q63B-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 3.5A)
 0.53A 2q63B-3u7sA:
20.2		 2q63B-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.35A 2q63B-3u7sA:
20.2		 2q63B-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q63_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.36A 2q63B-3u7sA:
20.2		 2q63B-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q64_B_1UNB1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 2q64A-3u7sA:
20.0		 2q64A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q64_B_1UNB1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.65A 2q64B-3u7sA:
20.1		 2q64B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Q64_B_1UNB1001_4
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		3 / 3 ASP A  29
THR A  80
PRO A  81
 017  A 201 (-3.2A)
None
017  A 202 (-4.0A)
 0.16A 2q64B-3u7sA:
20.1		 2q64B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.41A 2qakA-3u7sA:
20.1		 2qakA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.49A 2qakA-3u7sA:
20.1		 2qakA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.35A 2qakA-3u7sA:
20.1		 2qakA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 201 ( 3.5A)
 0.59A 2qakB-3u7sA:
20.2		 2qakB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_3
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.43A 2qakB-3u7sA:
20.2		 2qakB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QAK_A_1UNA1001_4
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		3 / 3 ASP A  29
THR A  80
PRO A  81
 017  A 201 (-3.2A)
None
017  A 202 (-4.0A)
 0.23A 2qakB-3u7sA:
20.2		 2qakB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 2qhcA-3u7sA:
19.8		 2qhcA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.45A 2qhcA-3u7sA:
19.8		 2qhcA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 2qhcB-3u7sA:
19.8		 2qhcB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2QHC_B_AB1B9001_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.38A 2qhcB-3u7sA:
19.8		 2qhcB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.49A 2r5pA-3u7sA:
20.3		 2r5pA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ASP A  29
GLY A  48
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.21A 2r5pA-3u7sA:
20.3		 2r5pA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
ASP A  30
ILE A  47
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 2r5pA-3u7sA:
20.3		 2r5pA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.45A 2r5pB-3u7sA:
20.2		 2r5pB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_B_MK1B902_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.68A 2r5pB-3u7sA:
20.2		 2r5pB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.49A 2r5pC-3u7sA:
20.3		 2r5pC-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ASP A  29
GLY A  48
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.21A 2r5pC-3u7sA:
20.3		 2r5pC-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
ASP A  30
ILE A  47
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 2r5pC-3u7sA:
20.3		 2r5pC-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.45A 2r5pD-3u7sA:
20.2		 2r5pD-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5P_D_MK1D902_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.69A 2r5pD-3u7sA:
20.2		 2r5pD-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_B_1UNB900_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.79A 2r5qA-3u7sA:
19.9		 2r5qA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_B_1UNB900_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 2r5qB-3u7sA:
20.2		 2r5qB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_D_1UND900_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.78A 2r5qC-3u7sA:
19.9		 2r5qC-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2R5Q_D_1UND900_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 2r5qD-3u7sA:
20.1		 2r5qD-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKF_A_AB1A501_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ALA A  22
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
 1.36A 2rkfA-3u7sA:
20.2		 2rkfA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKF_A_AB1A501_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.43A 2rkfA-3u7sA:
20.2		 2rkfA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKG_B_AB1B501_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.30A 2rkgA-3u7sA:
20.0		 2rkgA-3u7sA:
79.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKG_B_AB1B501_1
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.45A 2rkgA-3u7sA:
20.0		 2rkgA-3u7sA:
79.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKG_B_AB1B501_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.29A 2rkgB-3u7sA:
20.0		 2rkgB-3u7sA:
79.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2RKG_B_AB1B501_2
(PROTEASE RETROPEPSIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 2rkgB-3u7sA:
20.0		 2rkgB-3u7sA:
79.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.50A 2z54A-3u7sA:
19.9		 2z54A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.40A 2z54A-3u7sA:
19.9		 2z54A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Z54_A_AB1A200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 2z54B-3u7sA:
19.9		 2z54B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3BVB_B_017B401_1
(PROTEASE
(RETROPEPSIN))		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.75A 3bvbA-3u7sA:
20.1		 3bvbA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 3cywA-3u7sA:
19.9		 3cywA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.62A 3cywA-3u7sA:
19.9		 3cywA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 3cywA-3u7sA:
19.9		 3cywA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.20A 3cywB-3u7sA:
19.7		 3cywB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYW_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.38A 3cywB-3u7sA:
19.7		 3cywB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.62A 3cyxA-3u7sA:
19.9		 3cyxA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CYX_A_ROCA201_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.53A 3cyxB-3u7sA:
19.8		 3cyxB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 1.04A 3d1xA-3u7sA:
19.9		 3d1xA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.55A 3d1xA-3u7sA:
19.9		 3d1xA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.65A 3d1xA-3u7sA:
19.9		 3d1xA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1X_A_ROCA201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 3d1xB-3u7sA:
19.9		 3d1xB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 1.08A 3d1yA-3u7sA:
20.0		 3d1yA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.63A 3d1yA-3u7sA:
20.0		 3d1yA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.56A 3d1yA-3u7sA:
20.0		 3d1yA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Y_A_ROCA201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 3d1yB-3u7sA:
19.9		 3d1yB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  30
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
 0.51A 3d1zA-3u7sA:
19.9		 3d1zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.57A 3d1zA-3u7sA:
19.9		 3d1zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.70A 3d1zA-3u7sA:
19.9		 3d1zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.56A 3d1zA-3u7sA:
19.9		 3d1zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.64A 3d1zA-3u7sA:
19.9		 3d1zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D1Z_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.25A 3d1zB-3u7sA:
19.9		 3d1zB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 3d20A-3u7sA:
20.1		 3d20A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.32A 3d20B-3u7sA:
19.8		 3d20B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3D20_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.31A 3d20B-3u7sA:
19.8		 3d20B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  32
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.50A 3ebzA-3u7sA:
19.1		 3ebzA-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 3ebzA-3u7sA:
19.1		 3ebzA-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3ebzB-3u7sA:
19.3		 3ebzB-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EBZ_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 3ebzB-3u7sA:
19.3		 3ebzB-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_B_478B200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.40A 3ekpB-3u7sA:
19.8		 3ekpB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.40A 3ekpC-3u7sA:
20.2		 3ekpC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKP_C_478C200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.34A 3ekpD-3u7sA:
20.1		 3ekpD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKQ_A_ROCA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.32A 3ekqA-3u7sA:
19.5		 3ekqA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKQ_A_ROCA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.63A 3ekqA-3u7sA:
19.5		 3ekqA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKQ_A_ROCA100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.64A 3ekqB-3u7sA:
19.6		 3ekqB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_B_017B200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.25A 3ektA-3u7sA:
20.2		 3ektA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_B_017B200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.27A 3ektA-3u7sA:
20.2		 3ektA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_B_017B200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.40A 3ektB-3u7sA:
20.1		 3ektB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.32A 3ektC-3u7sA:
19.8		 3ektC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.32A 3ektC-3u7sA:
19.8		 3ektC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3ektD-3u7sA:
19.7		 3ektD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKT_D_017D200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.35A 3ektD-3u7sA:
19.7		 3ektD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKV_A_478A200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 3ekvA-3u7sA:
19.6		 3ekvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKV_A_478A200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 3ekvB-3u7sA:
19.3		 3ekvB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.65A 3ekwA-3u7sA:
19.7		 3ekwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.36A 3ekwA-3u7sA:
19.7		 3ekwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.47A 3ekwB-3u7sA:
19.7		 3ekwB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKW_B_DR7B100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 3ekwB-3u7sA:
19.7		 3ekwB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 0.99A 3ekxA-3u7sA:
19.6		 3ekxA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
THR A  80
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.49A 3ekxA-3u7sA:
19.6		 3ekxA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.44A 3ekxA-3u7sA:
19.6		 3ekxA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKX_B_1UNB201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.72A 3ekxB-3u7sA:
19.9		 3ekxB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKY_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.42A 3ekyA-3u7sA:
19.8		 3ekyA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKY_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 3ekyA-3u7sA:
19.8		 3ekyA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EKY_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
ASP A  25
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.68A 3ekyB-3u7sA:
19.5		 3ekyB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL0_A_1UNA201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 8 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.34A 3el0A-3u7sA:
19.2		 3el0A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL0_A_1UNA201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.72A 3el0B-3u7sA:
19.4		 3el0B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.41A 3el1A-3u7sA:
19.8		 3el1A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.41A 3el1A-3u7sA:
19.8		 3el1A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.42A 3el1A-3u7sA:
19.8		 3el1A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.48A 3el1B-3u7sA:
19.9		 3el1B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL1_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.61A 3el1B-3u7sA:
19.9		 3el1B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
VAL A  84
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
None
 1.00A 3el4A-3u7sA:
19.7		 3el4A-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
None
 0.58A 3el4A-3u7sA:
19.7		 3el4A-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
THR A  80
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
None
 0.56A 3el4A-3u7sA:
19.7		 3el4A-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL4_A_ROCA100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.56A 3el4B-3u7sA:
19.9		 3el4B-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL5_B_1UNB201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 3el5A-3u7sA:
19.6		 3el5A-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL5_B_1UNB201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.66A 3el5A-3u7sA:
19.6		 3el5A-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL5_B_1UNB201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
THR A  80
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
None
 0.36A 3el5B-3u7sA:
19.5		 3el5B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 8 ARG A   8
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.47A 3el9A-3u7sA:
19.4		 3el9A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 8 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.46A 3el9A-3u7sA:
19.4		 3el9A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.35A 3el9B-3u7sA:
19.8		 3el9B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EL9_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.63A 3el9B-3u7sA:
19.8		 3el9B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM3_B_478B200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 0.25A 3em3A-3u7sA:
19.8		 3em3A-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM3_B_478B200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.47A 3em3B-3u7sA:
19.9		 3em3B-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.49A 3em4A-3u7sA:
19.6		 3em4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_A_DR7A100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.62A 3em4A-3u7sA:
19.6		 3em4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_A_DR7A100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
ASP A  25
ALA A  28
ASP A  29
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.35A 3em4B-3u7sA:
19.9		 3em4B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_V_DR7V100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.44A 3em4U-3u7sA:
19.9		 3em4U-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_V_DR7V100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.54A 3em4U-3u7sA:
19.9		 3em4U-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM4_V_DR7V100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
ASP A  25
ASP A  29
ILE A  47
GLY A  48
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 3em4V-3u7sA:
20.0		 3em4V-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM6_A_017A200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.56A 3em6B-3u7sA:
19.8		 3em6B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EM6_A_017A200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 3em6B-3u7sA:
19.8		 3em6B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
 1.46A 3gguA-3u7sA:
20.0		 3gguA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
PRO A  81
VAL A  84
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
None
 0.43A 3gguA-3u7sA:
20.0		 3gguA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.38A 3gguA-3u7sA:
20.0		 3gguA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.31A 3gguB-3u7sA:
20.0		 3gguB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GGU_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.29A 3gguB-3u7sA:
20.0		 3gguB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_1
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.17A 3jvyA-3u7sA:
19.8		 3jvyA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_1
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.56A 3jvyA-3u7sA:
19.8		 3jvyA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_1
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 3jvyA-3u7sA:
19.8		 3jvyA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 3jvyB-3u7sA:
19.8		 3jvyB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 201 ( 3.5A)
 0.56A 3jvyB-3u7sA:
19.8		 3jvyB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3JVY_B_017B401_2
(GAG-POL POLYPROTEIN)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.34A 3jvyB-3u7sA:
19.8		 3jvyB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_B_ROCB201_4
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 4 ARG A   8
ASP A  29
GLY A  48
THR A  80
 None
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
None
 1.01A 3k4vB-3u7sA:
19.9		 3k4vB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.47A 3k4vC-3u7sA:
19.7		 3k4vC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.45A 3k4vC-3u7sA:
19.7		 3k4vC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 4 GLY A  27
ASP A  29
GLY A  48
THR A  80
 017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
None
 0.43A 3k4vC-3u7sA:
19.7		 3k4vC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.29A 3k4vD-3u7sA:
19.5		 3k4vD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.37A 3k4vD-3u7sA:
19.5		 3k4vD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K4V_D_ROCD201_3
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.58A 3k4vD-3u7sA:
19.5		 3k4vD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.26A 3lzsA-3u7sA:
19.8		 3lzsA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.36A 3lzsA-3u7sA:
19.8		 3lzsA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3lzsB-3u7sA:
19.7		 3lzsB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZS_A_017A200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.39A 3lzsB-3u7sA:
19.7		 3lzsB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZU_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3lzuA-3u7sA:
19.6		 3lzuA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZU_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.39A 3lzuA-3u7sA:
19.6		 3lzuA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.40A 3lzvA-3u7sA:
19.4		 3lzvA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.41A 3lzvA-3u7sA:
19.4		 3lzvA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LZV_A_017A200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.81A 3lzvB-3u7sA:
19.1		 3lzvB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.58A 3mwsA-3u7sA:
19.7		 3mwsA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.58A 3mwsA-3u7sA:
19.7		 3mwsA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 3mwsA-3u7sA:
19.7		 3mwsA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.52A 3mwsA-3u7sA:
19.7		 3mwsA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.42A 3mwsA-3u7sA:
19.7		 3mwsA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ARG A   8
LEU A  23
ASP A  25
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.50A 3mwsB-3u7sA:
19.6		 3mwsB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ARG A   8
LEU A  23
ASP A  25
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.62A 3mwsB-3u7sA:
19.6		 3mwsB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.44A 3mwsB-3u7sA:
19.6		 3mwsB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MWS_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.38A 3mwsB-3u7sA:
19.6		 3mwsB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3N3I_A_ROCA201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.19A 3n3iA-3u7sA:
14.0		 3n3iA-3u7sA:
38.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3N3I_A_ROCA201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.26A 3n3iA-3u7sA:
14.0		 3n3iA-3u7sA:
38.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_A_ROCA101_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.90A 3ndtB-3u7sA:
19.8		 3ndtB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_A_ROCA101_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.58A 3ndtB-3u7sA:
19.8		 3ndtB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.37A 3ndtC-3u7sA:
19.8		 3ndtC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.50A 3ndtC-3u7sA:
19.8		 3ndtC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 3ndtD-3u7sA:
19.6		 3ndtD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.35A 3ndtD-3u7sA:
19.6		 3ndtD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDT_D_ROCD100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.50A 3ndtD-3u7sA:
19.6		 3ndtD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.34A 3nduA-3u7sA:
19.5		 3nduA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.51A 3nduA-3u7sA:
19.5		 3nduA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.51A 3nduA-3u7sA:
19.5		 3nduA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.23A 3nduB-3u7sA:
19.8		 3nduB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.33A 3nduB-3u7sA:
19.8		 3nduB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_A_ROCA101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.49A 3nduB-3u7sA:
19.8		 3nduB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.48A 3nduC-3u7sA:
19.7		 3nduC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.50A 3nduC-3u7sA:
19.7		 3nduC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.50A 3nduD-3u7sA:
19.2		 3nduD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDU_D_ROCD100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.54A 3nduD-3u7sA:
19.2		 3nduD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.45A 3ndwA-3u7sA:
20.0		 3ndwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.61A 3ndwA-3u7sA:
20.0		 3ndwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.60A 3ndwB-3u7sA:
19.4		 3ndwB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDW_A_RITA100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.48A 3ndwB-3u7sA:
19.4		 3ndwB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.44A 3ndxA-3u7sA:
20.0		 3ndxA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 3ndxA-3u7sA:
20.0		 3ndxA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NDX_A_RITA100_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.58A 3ndxB-3u7sA:
19.5		 3ndxB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.60A 3nu3A-3u7sA:
19.8		 3nu3A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.77A 3nu3A-3u7sA:
19.8		 3nu3A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.51A 3nu3A-3u7sA:
19.8		 3nu3A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.64A 3nu3A-3u7sA:
19.8		 3nu3A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.48A 3nu3A-3u7sA:
19.8		 3nu3A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.75A 3nu3B-3u7sA:
19.6		 3nu3B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.28A 3nu3B-3u7sA:
19.6		 3nu3B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU3_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 3nu3B-3u7sA:
19.6		 3nu3B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU4_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  25
ALA A  28
ASP A  30
ILE A  32
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.54A 3nu4A-3u7sA:
19.8		 3nu4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU4_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.73A 3nu4A-3u7sA:
19.8		 3nu4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU4_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.28A 3nu4B-3u7sA:
19.5		 3nu4B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU4_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.26A 3nu4B-3u7sA:
19.5		 3nu4B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU5_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.60A 3nu5A-3u7sA:
19.9		 3nu5A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU5_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 3nu5A-3u7sA:
19.9		 3nu5A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU5_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.51A 3nu5B-3u7sA:
19.7		 3nu5B-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.76A 3nu6A-3u7sA:
19.7		 3nu6A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.64A 3nu6A-3u7sA:
19.7		 3nu6A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.75A 3nu6A-3u7sA:
19.7		 3nu6A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU6_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.24A 3nu6B-3u7sA:
19.9		 3nu6B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU9_A_478A401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 8 ASP A  25
ALA A  28
ASP A  30
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.51A 3nu9A-3u7sA:
19.7		 3nu9A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU9_A_478A401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 8 ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 3nu9A-3u7sA:
19.7		 3nu9A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NU9_A_478A401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.24A 3nu9B-3u7sA:
19.8		 3nu9B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.63A 3nujA-3u7sA:
19.9		 3nujA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.71A 3nujA-3u7sA:
19.9		 3nujA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3nujB-3u7sA:
19.7		 3nujB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUJ_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.23A 3nujB-3u7sA:
19.7		 3nujB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUO_B_478B478_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.67A 3nuoA-3u7sA:
19.9		 3nuoA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUO_B_478B478_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.83A 3nuoA-3u7sA:
19.9		 3nuoA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUO_B_478B478_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.28A 3nuoB-3u7sA:
19.6		 3nuoB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3NUO_B_478B478_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.28A 3nuoB-3u7sA:
19.6		 3nuoB-3u7sA:
77.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_A_017A200_1
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.47A 3ogpA-3u7sA:
15.5		 3ogpA-3u7sA:
28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_A_017A200_2
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 3ogpB-3u7sA:
15.4		 3ogpB-3u7sA:
28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_B_017B200_1
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.42A 3ogpA-3u7sA:
15.5		 3ogpA-3u7sA:
28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGP_B_017B200_2
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.32A 3ogpB-3u7sA:
15.4		 3ogpB-3u7sA:
28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGQ_A_AB1A200_1
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.50A 3ogqA-3u7sA:
15.4		 3ogqA-3u7sA:
28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OGQ_A_AB1A200_2
(FIV PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.42A 3ogqB-3u7sA:
15.4		 3ogqB-3u7sA:
28.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.28A 3oxcA-3u7sA:
19.2		 3oxcA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.57A 3oxcA-3u7sA:
19.2		 3oxcA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		3 / 3 ARG A   8
LEU A  23
THR A  80
 None
 0.39A 3oxcA-3u7sA:
19.2		 3oxcA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 3oxcB-3u7sA:
19.3		 3oxcB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXC_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.42A 3oxcB-3u7sA:
19.3		 3oxcB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_B_478B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 0.19A 3oxvA-3u7sA:
20.3		 3oxvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_B_478B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.67A 3oxvB-3u7sA:
19.8		 3oxvB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_B_478B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.57A 3oxvB-3u7sA:
19.8		 3oxvB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_C_478C200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 0.26A 3oxvC-3u7sA:
20.2		 3oxvC-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_C_478C200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.72A 3oxvD-3u7sA:
20.0		 3oxvD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXV_C_478C200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 3oxvD-3u7sA:
20.0		 3oxvD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_B_017B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 0.23A 3oxwA-3u7sA:
20.2		 3oxwA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_B_017B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.40A 3oxwB-3u7sA:
20.2		 3oxwB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_D_017D200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.24A 3oxwC-3u7sA:
20.2		 3oxwC-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXW_D_017D200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.36A 3oxwD-3u7sA:
20.0		 3oxwD-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 1.44A 3oxxA-3u7sA:
19.8		 3oxxA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.43A 3oxxA-3u7sA:
19.8		 3oxxA-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.46A 3oxxB-3u7sA:
20.1		 3oxxB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_A_DR7A100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 1.44A 3oxxB-3u7sA:
20.1		 3oxxB-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
 1.40A 3oxxC-3u7sA:
19.4		 3oxxC-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.55A 3oxxC-3u7sA:
19.4		 3oxxC-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.47A 3oxxD-3u7sA:
19.9		 3oxxD-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXX_C_DR7C100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.38A 3oxxD-3u7sA:
19.9		 3oxxD-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.61A 3oy4A-3u7sA:
19.3		 3oy4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.72A 3oy4A-3u7sA:
19.3		 3oy4A-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OY4_B_017B200_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.29A 3oy4B-3u7sA:
19.6		 3oy4B-3u7sA:
77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.45A 3pwmA-3u7sA:
19.9		 3pwmA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.29A 3pwmB-3u7sA:
19.7		 3pwmB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWM_B_017B402_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.36A 3pwmB-3u7sA:
19.7		 3pwmB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 3pwrA-3u7sA:
19.8		 3pwrA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.38A 3pwrA-3u7sA:
19.8		 3pwrA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.59A 3pwrA-3u7sA:
19.8		 3pwrA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PWR_A_ROCA401_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.44A 3pwrB-3u7sA:
19.8		 3pwrB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S43_A_478A401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.57A 3s43A-3u7sA:
19.9		 3s43A-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S43_A_478A401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.26A 3s43B-3u7sA:
19.6		 3s43B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S45_B_478B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ASP A  25
ALA A  28
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.61A 3s45A-3u7sA:
19.0		 3s45A-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S45_B_478B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.46A 3s45B-3u7sA:
19.3		 3s45B-3u7sA:
47.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  48
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 ( 4.6A)
 0.77A 3s53A-3u7sA:
18.6		 3s53A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.33A 3s53A-3u7sA:
18.6		 3s53A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  32
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.62A 3s53B-3u7sA:
19.7		 3s53B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S53_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 3s53B-3u7sA:
19.7		 3s53B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S54_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.55A 3s54A-3u7sA:
20.0		 3s54A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.58A 3s56A-3u7sA:
18.9		 3s56A-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
LEU A  23
ASP A  25
ASP A  29
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.32A 3s56B-3u7sA:
19.5		 3s56B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3S56_A_ROCA201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ARG A   8
LEU A  23
ASP A  25
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.50A 3s56B-3u7sA:
19.5		 3s56B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SO9_A_017A100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ALA A  28
ASP A  29
ASP A  30
ILE A  47
PRO A  81
VAL A  84
 None
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
None
 0.92A 3so9B-3u7sA:
19.3		 3so9B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SO9_A_017A100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.81A 3so9B-3u7sA:
19.3		 3so9B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_A_TPVA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ARG A   8
LEU A  23
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 3spkA-3u7sA:
19.9		 3spkA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_A_TPVA100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.44A 3spkA-3u7sA:
19.9		 3spkA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_B_TPVB100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
LEU A  23
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.56A 3spkA-3u7sA:
19.9		 3spkA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_B_TPVB100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.35A 3spkB-3u7sA:
20.0		 3spkB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SPK_B_TPVB100_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
None
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.46A 3spkB-3u7sA:
20.0		 3spkB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3T3C_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  50
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 201 ( 3.5A)
 0.25A 3t3cA-3u7sA:
19.0		 3t3cA-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3T3C_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
None
 0.69A 3t3cB-3u7sA:
19.0		 3t3cB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3T3C_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.74A 3t3cB-3u7sA:
19.0		 3t3cB-3u7sA:
69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.22A 3tkgA-3u7sA:
19.5		 3tkgA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.50A 3tkgA-3u7sA:
19.5		 3tkgA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.56A 3tkgA-3u7sA:
19.5		 3tkgA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.39A 3tkgB-3u7sA:
19.5		 3tkgB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_B_ROCB801_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.41A 3tkgB-3u7sA:
19.5		 3tkgB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.57A 3tkgC-3u7sA:
19.5		 3tkgC-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.33A 3tkgD-3u7sA:
19.6		 3tkgD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
GLY A  49
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.41A 3tkgD-3u7sA:
19.6		 3tkgD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKG_C_ROCC901_3
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		3 / 3 ASP A  29
THR A  80
PRO A  81
 017  A 201 (-3.2A)
None
017  A 202 (-4.0A)
 0.21A 3tkgD-3u7sA:
19.6		 3tkgD-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKW_B_017B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.24A 3tkwA-3u7sA:
20.1		 3tkwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TKW_B_017B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.28A 3tkwA-3u7sA:
20.1		 3tkwA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TL9_A_ROCA401_4
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 4 ASP A  29
ASP A  30
GLY A  48
THR A  80
 017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
 0.37A 3tl9B-3u7sA:
18.6		 3tl9B-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
LEU A  82
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
017  A 202 (-4.0A)
 1.30A 3ttpA-3u7sA:
20.3		 3ttpA-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
LEU A  82
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
017  A 202 (-4.0A)
 0.46A 3ttpA-3u7sA:
20.3		 3ttpA-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
LEU A  82
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
017  A 202 (-4.0A)
 1.32A 3ttpB-3u7sA:
20.2		 3ttpB-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3TTP_A_017A201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
LEU A  82
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
017  A 202 (-4.0A)
 0.42A 3ttpB-3u7sA:
20.2		 3ttpB-3u7sA:
83.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.30A 3ucbA-3u7sA:
19.5		 3ucbA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  32
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.40A 3ucbA-3u7sA:
19.5		 3ucbA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.23A 3ucbB-3u7sA:
19.9		 3ucbB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  32
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.51A 3ucbB-3u7sA:
19.9		 3ucbB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UCB_B_017B202_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 TRP A  42
PRO A  44
GLY A  78
PRO A  79
 None
 0.30A 3ucbB-3u7sA:
19.9		 3ucbB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ASP A  25
ALA A  28
ASP A  30
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.46A 3ufnA-3u7sA:
19.6		 3ufnA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  48
GLY A  49
ILE A  50
THR A  80
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.57A 3ufnA-3u7sA:
19.6		 3ufnA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 11 ASP A  25
GLY A  27
ALA A  28
GLY A  49
THR A  80
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
None
 0.75A 3ufnA-3u7sA:
19.6		 3ufnA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UFN_A_ROCA401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 7 ARG A   8
ASP A  25
GLY A  49
ILE A  50
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.61A 3ufnB-3u7sA:
19.7		 3ufnB-3u7sA:
80.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WSJ_A_MK1A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
 0.50A 3wsjA-3u7sA:
12.9		 3wsjA-3u7sA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WSJ_A_MK1A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
 1.41A 3wsjA-3u7sA:
12.9		 3wsjA-3u7sA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WSJ_A_MK1A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
LEU A  76
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
 0.60A 3wsjA-3u7sA:
12.9		 3wsjA-3u7sA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WSJ_A_MK1A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 ARG A   8
LEU A  23
ASP A  25
ALA A  28
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
 0.41A 3wsjB-3u7sA:
13.1		 3wsjB-3u7sA:
29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 TYR A  59
VAL A  75
ILE A  64
GLU A  35
 None
 1.09A 4a97H-3u7sA:
undetectable		 4a97H-3u7sA:
14.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQB_B_017B101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.74A 4dqbA-3u7sA:
19.7		 4dqbA-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQB_B_017B101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.30A 4dqbB-3u7sA:
19.7		 4dqbB-3u7sA:
75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.70A 4dqcA-3u7sA:
19.4		 4dqcA-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.33A 4dqcB-3u7sA:
20.1		 4dqcB-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQC_A_017A101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.27A 4dqcB-3u7sA:
20.1		 4dqcB-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.63A 4dqeA-3u7sA:
19.6		 4dqeA-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.34A 4dqeB-3u7sA:
20.1		 4dqeB-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQE_B_017B101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.26A 4dqeB-3u7sA:
20.1		 4dqeB-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQF_B_017B101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.59A 4dqfA-3u7sA:
18.1		 4dqfA-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQF_B_017B101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.78A 4dqfA-3u7sA:
18.1		 4dqfA-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQF_B_017B101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.31A 4dqfB-3u7sA:
19.2		 4dqfB-3u7sA:
73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_1
(WILD-TYPE HIV-1
PROTEASE DIMER)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.67A 4dqhA-3u7sA:
19.7		 4dqhA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_2
(WILD-TYPE HIV-1
PROTEASE DIMER)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.36A 4dqhB-3u7sA:
20.1		 4dqhB-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4DQH_B_017B101_2
(WILD-TYPE HIV-1
PROTEASE DIMER)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.31A 4dqhB-3u7sA:
20.1		 4dqhB-3u7sA:
74.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4E1G_B_LNLB701_2
(PROSTAGLANDIN G/H
SYNTHASE 2)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 7 VAL A  13
VAL A  11
LEU A  10
ASN A  88
 None
 0.74A 4e1gB-3u7sA:
undetectable		 4e1gB-3u7sA:
10.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.49A 4hlaA-3u7sA:
20.0		 4hlaA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.27A 4hlaA-3u7sA:
20.0		 4hlaA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.34A 4hlaA-3u7sA:
20.0		 4hlaA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HLA_A_017A200_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.29A 4hlaB-3u7sA:
19.9		 4hlaB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4J5J_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.65A 4j5jB-3u7sA:
19.6		 4j5jB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.67A 4jecB-3u7sA:
20.0		 4jecB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.79A 4jecB-3u7sA:
20.0		 4jecB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.55A 4jecB-3u7sA:
20.0		 4jecB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 4jecB-3u7sA:
20.0		 4jecB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4JEC_B_478B401_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.41A 4jecB-3u7sA:
20.0		 4jecB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4L1A_A_AB1A101_1
(MDR769 HIV-1
PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
GLY A  27
ALA A  28
ASP A  29
ASP A  30
THR A  80
PRO A  81
VAL A  84
 None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
None
 0.62A 4l1aA-3u7sA:
17.9		 4l1aA-3u7sA:
81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.28A 4ll3B-3u7sA:
20.1		 4ll3B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.24A 4ll3B-3u7sA:
20.1		 4ll3B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.31A 4ll3A-3u7sA:
20.0		 4ll3A-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.27A 4ll3A-3u7sA:
20.0		 4ll3A-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4LL3_A_017A202_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.34A 4ll3B-3u7sA:
20.1		 4ll3B-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_B_017B101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.62A 4njtA-3u7sA:
19.9		 4njtA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_B_017B101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.57A 4njtA-3u7sA:
19.9		 4njtA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_B_017B101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.21A 4njtB-3u7sA:
20.5		 4njtB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_D_017D101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.69A 4njtC-3u7sA:
20.0		 4njtC-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_D_017D101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.60A 4njtC-3u7sA:
20.0		 4njtC-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJT_D_017D101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 201 ( 3.5A)
 0.14A 4njtD-3u7sA:
20.5		 4njtD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.52A 4njuA-3u7sA:
20.2		 4njuA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.32A 4njuA-3u7sA:
20.2		 4njuA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 LEU A  82
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 (-4.0A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.95A 4njuA-3u7sA:
20.2		 4njuA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_A_TPVA500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.60A 4njuB-3u7sA:
19.9		 4njuB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 4njuC-3u7sA:
20.1		 4njuC-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.28A 4njuC-3u7sA:
20.1		 4njuC-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 LEU A  82
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 (-4.0A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.94A 4njuC-3u7sA:
20.1		 4njuC-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJU_C_TPVC500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ARG A   8
LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.61A 4njuD-3u7sA:
20.0		 4njuD-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.48A 4njvA-3u7sA:
20.1		 4njvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.39A 4njvA-3u7sA:
20.1		 4njvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.56A 4njvA-3u7sA:
20.1		 4njvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.56A 4njvA-3u7sA:
20.1		 4njvA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_A_RITA500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
GLY A  27
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 4njvB-3u7sA:
20.1		 4njvB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 11 ARG A   8
ASP A  25
GLY A  27
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.69A 4njvC-3u7sA:
20.2		 4njvC-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.46A 4njvD-3u7sA:
20.1		 4njvD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.52A 4njvD-3u7sA:
20.1		 4njvD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NJV_D_RITD500_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  47
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
 0.44A 4njvD-3u7sA:
20.1		 4njvD-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4NPT_A_017A401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ALA A  28
ILE A  47
GLY A  48
THR A  80
VAL A  84
 017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 ( 4.6A)
None
None
 0.59A 4nptA-3u7sA:
18.8		 4nptA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.29A 4q1wA-3u7sA:
19.8		 4q1wA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ARG A   8
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.66A 4q1wB-3u7sA:
19.2		 4q1wB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ARG A   8
ASP A  25
ALA A  28
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.87A 4q1wB-3u7sA:
19.2		 4q1wB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1W_A_017A104_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.56A 4q1wB-3u7sA:
19.2		 4q1wB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1X_A_017A101_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 11 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
ILE A  47
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.40A 4q1xA-3u7sA:
19.8		 4q1xA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1X_A_017A101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  32
ILE A  47
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.78A 4q1xB-3u7sA:
19.4		 4q1xB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1X_A_017A101_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  32
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.75A 4q1xB-3u7sA:
19.4		 4q1xB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  48
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 ( 4.6A)
 0.77A 4q1yA-3u7sA:
20.0		 4q1yA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_1
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 10 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.31A 4q1yA-3u7sA:
20.0		 4q1yA-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.58A 4q1yB-3u7sA:
19.4		 4q1yB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
ILE A  32
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.59A 4q1yB-3u7sA:
19.4		 4q1yB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 4q1yB-3u7sA:
19.4		 4q1yB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q1Y_A_017A106_2
(ASPARTYL PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ILE A  32
ILE A  47
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.51A 4q1yB-3u7sA:
19.4		 4q1yB-3u7sA:
80.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q5M_A_ROCA1101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 GLY A  27
ASP A  29
ILE A  50
THR A  80
PRO A  81
 017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 201 ( 3.5A)
None
017  A 202 (-4.0A)
 0.55A 4q5mA-3u7sA:
17.0		 4q5mA-3u7sA:
38.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4Q5M_A_ROCA1101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 GLY A  27
ASP A  29
GLY A  49
ILE A  50
PRO A  81
 017  A 201 ( 3.5A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 4q5mA-3u7sA:
17.0		 4q5mA-3u7sA:
38.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QGI_A_ROCA101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 11 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.63A 4qgiA-3u7sA:
19.6		 4qgiA-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QGI_A_ROCA101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.60A 4qgiB-3u7sA:
19.1		 4qgiB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QGI_A_ROCA101_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.63A 4qgiB-3u7sA:
19.1		 4qgiB-3u7sA:
78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.57A 4rvjA-3u7sA:
19.9		 4rvjA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.76A 4rvjA-3u7sA:
19.9		 4rvjA-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.29A 4rvjB-3u7sA:
19.8		 4rvjB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_B_478B101_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.30A 4rvjB-3u7sA:
19.8		 4rvjB-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 11 LEU A  23
ASP A  25
ALA A  28
ASP A  30
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.58A 4rvjC-3u7sA:
19.9		 4rvjC-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 11 LEU A  23
ASP A  25
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.77A 4rvjC-3u7sA:
19.9		 4rvjC-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
ASP A  25
ALA A  28
ASP A  29
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.28A 4rvjD-3u7sA:
19.8		 4rvjD-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RVJ_D_478D101_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.29A 4rvjD-3u7sA:
19.8		 4rvjD-3u7sA:
79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4YOA_A_017A100_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		4 / 6 ASP A  29
THR A  80
PRO A  81
VAL A  84
 017  A 201 (-3.2A)
None
017  A 202 (-4.0A)
None
 0.28A 4yoaA-3u7sA:
18.6		 4yoaA-3u7sA:
81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5J_A_017A201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.24A 5e5jA-3u7sA:
20.0		 5e5jA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5J_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  32
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.55A 5e5jB-3u7sA:
20.1		 5e5jB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5J_A_017A201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 5e5jB-3u7sA:
20.1		 5e5jB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.33A 5e5kA-3u7sA:
20.0		 5e5kA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.25A 5e5kA-3u7sA:
20.0		 5e5kA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.50A 5e5kB-3u7sA:
20.1		 5e5kB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5E5K_B_017B201_2
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.23A 5e5kB-3u7sA:
20.1		 5e5kB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_1
(PROTEASE E35D-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ALA A  28
ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 0.99A 5kqxA-3u7sA:
19.7		 5kqxA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_1
(PROTEASE E35D-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.69A 5kqxA-3u7sA:
19.7		 5kqxA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_1
(PROTEASE E35D-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
THR A  80
PRO A  81
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
None
017  A 202 (-4.0A)
 0.47A 5kqxA-3u7sA:
19.7		 5kqxA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQX_A_ROCA101_2
(PROTEASE E35D-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
LEU A  23
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.39A 5kqxB-3u7sA:
19.9		 5kqxB-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_1
(PROTEASE E35D-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ALA A  28
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 0.47A 5kqyA-3u7sA:
19.9		 5kqyA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_1
(PROTEASE E35D-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.57A 5kqyA-3u7sA:
19.9		 5kqyA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_1
(PROTEASE E35D-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ALA A  28
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.55A 5kqyA-3u7sA:
19.9		 5kqyA-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KQY_B_017B101_2
(PROTEASE E35D-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 7 GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.22A 5kqyB-3u7sA:
20.0		 5kqyB-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR0_A_478A101_1
(PROTEASE E35D-APV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.76A 5kr0A-3u7sA:
19.8		 5kr0A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR0_A_478A101_2
(PROTEASE E35D-APV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 LEU A  23
GLY A  27
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.28A 5kr0B-3u7sA:
19.8		 5kr0B-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR1_B_017B101_1
(PROTEASE PR5-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 10 ARG A   8
LEU A  23
ALA A  28
ASP A  30
ILE A  47
 None
None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
 0.90A 5kr1A-3u7sA:
19.5		 5kr1A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR1_B_017B101_1
(PROTEASE PR5-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 ARG A   8
LEU A  23
ALA A  28
ILE A  47
GLY A  49
ILE A  50
 None
None
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.97A 5kr1A-3u7sA:
19.5		 5kr1A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR1_B_017B101_2
(PROTEASE PR5-DRV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 8 GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
 017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.33A 5kr1B-3u7sA:
19.9		 5kr1B-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 9 ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
THR A  80
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.79A 5kr2A-3u7sA:
19.0		 5kr2A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ALA A  28
ASP A  29
ASP A  30
ILE A  47
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
None
017  A 202 (-4.0A)
 0.48A 5kr2A-3u7sA:
19.0		 5kr2A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 0.92A 5kr2A-3u7sA:
19.0		 5kr2A-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_2
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 11 ARG A   8
LEU A  23
ASP A  30
ILE A  47
PRO A  81
 None
None
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-4.0A)
 1.04A 5kr2B-3u7sA:
19.9		 5kr2B-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_2
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ALA A  28
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 None
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.75A 5kr2B-3u7sA:
19.9		 5kr2B-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_A_ROCA101_2
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 11 LEU A  23
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.53A 5kr2B-3u7sA:
19.9		 5kr2B-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_C_ROCC101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
THR A  80
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.66A 5kr2C-3u7sA:
19.2		 5kr2C-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_C_ROCC101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
THR A  80
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
 0.72A 5kr2C-3u7sA:
19.2		 5kr2C-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_C_ROCC101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ALA A  28
ASP A  29
ASP A  30
ILE A  47
THR A  80
PRO A  81
 017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
None
017  A 202 (-4.0A)
 0.63A 5kr2C-3u7sA:
19.2		 5kr2C-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_C_ROCC101_1
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 9 ASP A  29
ASP A  30
GLY A  48
THR A  80
PRO A  81
 017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
None
017  A 202 (-4.0A)
 0.91A 5kr2C-3u7sA:
19.2		 5kr2C-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5KR2_C_ROCC101_2
(PROTEASE PR5-SQV)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 9 ARG A   8
LEU A  23
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.55A 5kr2D-3u7sA:
20.0		 5kr2D-3u7sA:
74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.29A 5t2zA-3u7sA:
19.8		 5t2zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.36A 5t2zA-3u7sA:
19.8		 5t2zA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.38A 5t2zB-3u7sA:
19.7		 5t2zB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T2Z_B_017B201_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.30A 5t2zB-3u7sA:
19.7		 5t2zB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T8H_B_478B401_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.37A 5t8hA-3u7sA:
19.9		 5t8hA-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T8H_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
ILE A  32
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.57A 5t8hB-3u7sA:
20.0		 5t8hB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5T8H_B_478B401_2
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  32
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
None
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.60A 5t8hB-3u7sA:
20.0		 5t8hB-3u7sA:
76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.49A 6dgxA-3u7sA:
20.0		 6dgxA-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.39A 6dgxA-3u7sA:
20.0		 6dgxA-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
LEU A  76
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.59A 6dgxB-3u7sA:
19.6		 6dgxB-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.70A 6dgxB-3u7sA:
19.6		 6dgxB-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.51A 6dgxB-3u7sA:
19.6		 6dgxB-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DGX_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
GLY A  49
LEU A  76
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.48A 6dgxB-3u7sA:
19.6		 6dgxB-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH0_A_017A101_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
None
 0.48A 6dh0A-3u7sA:
19.8		 6dh0A-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH0_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  30
LEU A  76
PRO A  81
VAL A  84
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
None
 0.58A 6dh0B-3u7sA:
19.7		 6dh0B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH0_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
None
 0.57A 6dh0B-3u7sA:
19.7		 6dh0B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH0_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ASP A  25
GLY A  27
ALA A  28
GLY A  49
LEU A  76
PRO A  81
VAL A  84
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
None
 0.50A 6dh0B-3u7sA:
19.7		 6dh0B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH3_A_017A101_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 1.48A 6dh3A-3u7sA:
20.0		 6dh3A-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH3_A_017A101_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.43A 6dh3A-3u7sA:
20.0		 6dh3A-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH3_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-4.0A)
 0.47A 6dh3B-3u7sA:
19.7		 6dh3B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH3_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.61A 6dh3B-3u7sA:
19.7		 6dh3B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH3_A_017A101_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.61A 6dh3B-3u7sA:
19.7		 6dh3B-3u7sA:
80.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH6_A_017A104_0
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
 0.38A 6dh6A-3u7sA:
20.0		 6dh6A-3u7sA:
78.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH6_A_017A104_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ASP A  30
LEU A  76
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
None
017  A 202 (-4.0A)
 0.59A 6dh6B-3u7sA:
19.6		 6dh6B-3u7sA:
78.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DH6_A_017A104_1
(PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		8 / 12 LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
LEU A  76
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
None
017  A 202 (-4.0A)
 0.49A 6dh6B-3u7sA:
19.6		 6dh6B-3u7sA:
78.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIF_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.36A 6difA-3u7sA:
20.0		 6difA-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIF_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.46A 6difA-3u7sA:
20.0		 6difA-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIF_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 202 (-4.0A)
 0.47A 6difA-3u7sA:
20.0		 6difA-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIF_B_TPVB201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.57A 6difB-3u7sA:
19.5		 6difB-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIL_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.54A 6dilA-3u7sA:
19.9		 6dilA-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIL_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
LEU A  23
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.30A 6dilA-3u7sA:
19.9		 6dilA-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIL_B_TPVB201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		5 / 12 LEU A  82
ASP A  30
ILE A  47
GLY A  49
ILE A  50
 017  A 202 (-4.0A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 0.95A 6dilA-3u7sA:
19.9		 6dilA-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DIL_B_TPVB201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ARG A   8
LEU A  23
ASP A  25
GLY A  27
ALA A  28
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.55A 6dilB-3u7sA:
19.6		 6dilB-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ1_B_AB1B201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		9 / 12 ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
GLY A  48
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 ( 4.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.59A 6dj1A-3u7sA:
19.9		 6dj1A-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ1_B_AB1B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.42A 6dj1B-3u7sA:
19.7		 6dj1B-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ1_B_AB1B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.73A 6dj1B-3u7sA:
19.7		 6dj1B-3u7sA:
77.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ2_B_AB1B201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		7 / 10 ASP A  25
ALA A  28
ASP A  29
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.66A 6dj2A-3u7sA:
19.8		 6dj2A-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ2_B_AB1B201_0
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 10 ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
PRO A  81
 017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 1.32A 6dj2A-3u7sA:
19.8		 6dj2A-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ2_B_AB1B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		6 / 12 ARG A   8
ASP A  25
ALA A  28
ASP A  30
GLY A  49
ILE A  50
 None
017  A 202 ( 2.5A)
017  A 201 (-3.4A)
017  A 201 ( 4.0A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
 1.43A 6dj2B-3u7sA:
19.6		 6dj2B-3u7sA:
76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DJ2_B_AB1B201_1
(HIV-1 PROTEASE)		 3u7s POL POLYPROTEIN
(Human
immunodeficiency
virus
1) 		10 / 12 ARG A   8
ASP A  25
GLY A  27
ALA A  28
ASP A  29
ASP A  30
ILE A  47
GLY A  49
ILE A  50
PRO A  81
 None
017  A 202 ( 2.5A)
017  A 201 ( 3.5A)
017  A 201 (-3.4A)
017  A 201 (-3.2A)
017  A 201 ( 4.0A)
017  A 202 (-3.6A)
017  A 202 (-2.9A)
017  A 201 ( 3.5A)
017  A 202 (-4.0A)
 0.70A 6dj2B-3u7sA:
19.6		 6dj2B-3u7sA:
76.25